MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer
Open Access
- 18 November 2024
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 28 (3) , 745-747
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- The current landscape of stereotactic body radiation therapy for metastatic castration-resistant prostate cancerProstate Cancer and Prostatic Diseases, 2024
- Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate CancerJAMA Oncology, 2023
- Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusRadiotherapy and Oncology, 2022
- Combination radionuclide therapy: A new paradigmNuclear Medicine and Biology, 2021
- Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus documentRadiotherapy and Oncology, 2020
- Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate CancerJAMA Oncology, 2020
- Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendationThe Lancet Oncology, 2020
- The biology of prostate cancer metastasesCurrent Opinion in Urology, 2017
- Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerationsNature Reviews Urology, 2016